| Title |
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, August 2019
|
| DOI | 10.1186/s40425-019-0679-9 |
| Pubmed ID | |
| Authors |
Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki, Ichinosuke Hyodo |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Italy | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 12% |
| Student > Master | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Researcher | 3 | 7% |
| Student > Doctoral Student | 2 | 5% |
| Other | 7 | 17% |
| Unknown | 16 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 22% |
| Computer Science | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 5 | 12% |
| Unknown | 18 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2019.
All research outputs
#14,975,050
of 25,462,162 outputs
Outputs from Journal for Immunotherapy of Cancer
#2,433
of 3,436 outputs
Outputs of similar age
#178,366
of 353,858 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#74
of 92 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,436 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,858 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.